Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,